Skip to main content
NVDA-2.15%AAPL+1.33%GOOGL-0.14%MSFT-0.19%AMZN-0.04%TSM-1.84%SPCX+1.81%AVGO-0.20%META-0.07%TSLA-0.22%SKHY-4.72%MU-3.43%BRK-B+0.06%LLY+0.60%JPM-0.43%AMD-2.31%WMT+0.81%V-0.29%XOM-0.46%ASMLa-2.21%JNJ+0.11%INTC-5.28%MA-0.24%0700.HK-1.94%ORCL-2.05%1398.HK+0.79%BAC-0.09%ABBV+0.77%CSCO-0.26%CVX-1.01%COST+0.14%LRCX-3.69%KO+1.14%CAT-0.70%AMAT-1.87%0005.HK-0.78%AP2d-1.11%UNH+0.33%DELL-3.31%HSBA.L-0.98%MS+0.02%PG+0.08%GE+0.44%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.20%HD-0.86%GS-0.13%0939.HK+1.66%NZDJPY-2.67%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.52%GBPJPY-1.47%CADJPY-1.45%EURJPY-1.43%EURNZD+1.28%NZDCAD-1.23%GBPNZD+1.22%NZDUSD-1.18%NZDCHF-1.02%USDNOK+0.96%EURNOK+0.88%CHFNOK+0.85%NOKJPY-0.75%AUDNZD+0.74%USDZAR+0.67%USDSEK+0.61%EURZAR+0.58%USDMXN+0.57%AUDDKK-0.56%AUDCAD-0.54%EURAUD+0.54%EURSEK+0.53%CHFSEK+0.49%GBPZAR+0.49%AUDSGD-0.48%GBPAUD+0.48%AUDUSD-0.45%GBPTRY+0.41%USDTHB+0.38%GBPHKD+0.32%AUDNOK+0.31%NZDSGD-0.29%GBPMXN-0.28%AUDCHF-0.28%USDPLN+0.27%EURCHF+0.24%CADCHF+0.21%GBPCHF+0.20%EURPLN+0.19%USDCHF+0.17%USDSGD+0.17%USDILS+0.16%USDTRY+0.11%EURHKD-0.10%NZDMXN+0.10%USDDKK+0.09%EURSGD+0.08%EURUSD+0.08%PLNJPY-0.06%USDCAD-0.06%GBPUSD+0.05%EURGBP+0.05%EURCZK-0.05%CHFSGD+0.05%SGDJPY+0.05%USDCOP-0.04%USDCNH+0.03%GBPCAD-0.03%EURCNH-0.03%EURCAD+0.02%GBPSGD-0.02%USDHKD0.00%EURDKK0.00%XPTUSD-4.05%HG1-4.03%GAGUSD-3.64%XAGUSD-3.64%UKOIL+1.91%COFFEE-1.84%USOIL+1.73%W1-0.92%COCOA-0.78%GAUUSD-0.64%XAUUSD-0.63%C1-0.56%BTCUSD-1.24%ETHUSD-1.02%USDTUSD-0.06%XRPUSD-1.98%SOLUSD-1.46%TRXUSDT0.00%ZECUSDT-5.46%DOGEUSD-2.43%XMRUSDT-1.64%LINKUSD-0.97%XLMUSD-1.58%BCHUSDT-9.07%LTCUSD-1.45%UNIUSD-3.79%HBARUSDT-1.63%TONUSD+24.88%SUIUSD-2.90%TAOUSDT-4.20%AAVEUSD-2.75%DOTUSDT-3.16%ICPUSDT-0.72%ONDOUSDT-2.53%WLDUSDT-2.43%ATOMUSDT-3.24%ARBUSDT+1.19%JUPUSDT-2.53%INJUSDT-3.51%STXUSDT-3.07%FETUSDT-2.98%TIAUSDT-0.34%PYTHUSDT-0.58%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-2.81%OPUSDT-3.00%IOTAUSDT-3.05%POLUSDT-6.22%AXSUSDT-2.25%FARTCOINUSDT-1.70%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.21%GALAUSDT-3.65%NOTUSDT-1.83%RONINUSDT-2.64%NVDA-2.15%AAPL+1.33%GOOGL-0.14%MSFT-0.19%AMZN-0.04%TSM-1.84%SPCX+1.81%AVGO-0.20%META-0.07%TSLA-0.22%SKHY-4.72%MU-3.43%BRK-B+0.06%LLY+0.60%JPM-0.43%AMD-2.31%WMT+0.81%V-0.29%XOM-0.46%ASMLa-2.21%JNJ+0.11%INTC-5.28%MA-0.24%0700.HK-1.94%ORCL-2.05%1398.HK+0.79%BAC-0.09%ABBV+0.77%CSCO-0.26%CVX-1.01%COST+0.14%LRCX-3.69%KO+1.14%CAT-0.70%AMAT-1.87%0005.HK-0.78%AP2d-1.11%UNH+0.33%DELL-3.31%HSBA.L-0.98%MS+0.02%PG+0.08%GE+0.44%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.20%HD-0.86%GS-0.13%0939.HK+1.66%NZDJPY-2.67%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.52%GBPJPY-1.47%CADJPY-1.45%EURJPY-1.43%EURNZD+1.28%NZDCAD-1.23%GBPNZD+1.22%NZDUSD-1.18%NZDCHF-1.02%USDNOK+0.96%EURNOK+0.88%CHFNOK+0.85%NOKJPY-0.75%AUDNZD+0.74%USDZAR+0.67%USDSEK+0.61%EURZAR+0.58%USDMXN+0.57%AUDDKK-0.56%AUDCAD-0.54%EURAUD+0.54%EURSEK+0.53%CHFSEK+0.49%GBPZAR+0.49%AUDSGD-0.48%GBPAUD+0.48%AUDUSD-0.45%GBPTRY+0.41%USDTHB+0.38%GBPHKD+0.32%AUDNOK+0.31%NZDSGD-0.29%GBPMXN-0.28%AUDCHF-0.28%USDPLN+0.27%EURCHF+0.24%CADCHF+0.21%GBPCHF+0.20%EURPLN+0.19%USDCHF+0.17%USDSGD+0.17%USDILS+0.16%USDTRY+0.11%EURHKD-0.10%NZDMXN+0.10%USDDKK+0.09%EURSGD+0.08%EURUSD+0.08%PLNJPY-0.06%USDCAD-0.06%GBPUSD+0.05%EURGBP+0.05%EURCZK-0.05%CHFSGD+0.05%SGDJPY+0.05%USDCOP-0.04%USDCNH+0.03%GBPCAD-0.03%EURCNH-0.03%EURCAD+0.02%GBPSGD-0.02%USDHKD0.00%EURDKK0.00%XPTUSD-4.05%HG1-4.03%GAGUSD-3.64%XAGUSD-3.64%UKOIL+1.91%COFFEE-1.84%USOIL+1.73%W1-0.92%COCOA-0.78%GAUUSD-0.64%XAUUSD-0.63%C1-0.56%BTCUSD-1.24%ETHUSD-1.02%USDTUSD-0.06%XRPUSD-1.98%SOLUSD-1.46%TRXUSDT0.00%ZECUSDT-5.46%DOGEUSD-2.43%XMRUSDT-1.64%LINKUSD-0.97%XLMUSD-1.58%BCHUSDT-9.07%LTCUSD-1.45%UNIUSD-3.79%HBARUSDT-1.63%TONUSD+24.88%SUIUSD-2.90%TAOUSDT-4.20%AAVEUSD-2.75%DOTUSDT-3.16%ICPUSDT-0.72%ONDOUSDT-2.53%WLDUSDT-2.43%ATOMUSDT-3.24%ARBUSDT+1.19%JUPUSDT-2.53%INJUSDT-3.51%STXUSDT-3.07%FETUSDT-2.98%TIAUSDT-0.34%PYTHUSDT-0.58%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-2.81%OPUSDT-3.00%IOTAUSDT-3.05%POLUSDT-6.22%AXSUSDT-2.25%FARTCOINUSDT-1.70%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.21%GALAUSDT-3.65%NOTUSDT-1.83%RONINUSDT-2.64%
BT

Bicara Therapeutics Inc. Common Stock (BCAX)

NASDAQ • Healthcare

$23.64
-$0.07 (-0.3%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$23.37
Previous Close$23.64
Day Range$23.1 - $23.98
Avg. Volume (3M)514.4K
Market Cap$1.5B
52 Week Range
$10.3$30.99
Next EarningsIn 60 daysNov 9, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$185.3M
EPS (TTM)
-$3.1
ROA (TTM)
-36.19%
Current Ratio
11.59

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+5.6%Q1 2026-$0.68
-45.3%Q2 2026-$0.93
0.0%Q3 2026-$0.82
Next

Nov 9

in 60 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -0.0%

Bicara Therapeutics’ second fiscal quarter of 2026 results pointed to wider year-over-year losses, based on preliminary figures released August 11, 2026. GAAP net income was a loss of about $55.4 million, down 102.4% from a loss of roughly $27.4 million a year ago, while EPS came in at -$0.82 versus -$0.50 a year earlier (down 64.0%). The company reported GAAP operating income of about -$60.0 million, consistent with its profile as a clinical-stage biotechnology developer focused on solid-tumor therapies such as ficerafusp alfa. Cash use also remained elevated, with negative operating cash flow of roughly $44.2 million in the quarter. For the next period, consensus calls for EPS of -$0.85.

View full earnings history

About Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector that develops therapies for solid tumors. Founded in 2018 and based in Boston, Bicara operates as a small-cap clinical-stage drug developer and has been public since September 2024.

Name
Bicara Therapeutics Inc. Common Stock
CEO
Claire Mazumdar Clemon
Website
www.bicara.com
Industry
Healthcare
Year Founded
2018
Employees
103

Today's Snapshot

AI-generated

Yesterday BCAX finished slightly down at 23.64.

Trading Volume

Above 10d avg 467.1K

550.2K

vs S&P 500 Today

Moderate Outperformance

+0.18%

Updated: September 10, 2026 at 12:09 UTC

Technical Indicators

1 Buy3 Neutral4 Sell
BCAX exhibits short-term weakness while longer-term support remains intact, as the stock trades below its 10- to 50-day averages yet remains above the 200-day moving average. Momentum indicators are modestly negative with an RSI in the low 40s and a mildly negative MACD, and trend strength is moderate per the ADX. Volatility is notable per the ATR and on-balance volume is weak, which supports the sell signal, while the classic pivot sits near the current price offering a nearby reference. Technical takeaway: Sell—short- to medium-term pressure outweighs longer-term support.
All signals
  • EMA (5 indicators)$21.35 - $24.80
    Sell
  • RSI (14)43.89
    Neutral
  • Stochastic %K (14, 3, 3)27.64
    Neutral
  • MACD Level (12, 26)-0.67
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24+5.7%
MRVIMaravai LifeSciences Holdings, Inc.
$6.95-3.3%
SEPNSepterna Inc
$37.97+1.6%
FTREFortrea Holdings Inc.
$16.79-1.6%
SVRASavara Inc.
$5.42-2.0%
KURAKura Oncology, Inc.
$12.09-3.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.